From the blog

A New T-Cell Treatment is Being Tested on Mesothelioma Patients

A new clinical trial at the Memorial Sloan Kettering Cancer Center is recruiting patients for a pleural mesothelioma study. The treatment involves T-cell therapy and is a very promising treatment for mesothelioma sufferers. The reason the study is being done is ATA2271, which is known as CAR T-cell therapy, was[…]

Read More »

Opdivo and Yervoy Have Been Fully Approved for Treating Mesothelioma

A new treatment has been approved for mesothelioma by the Food and Drug Administration (FDA). The treatment uses a combination of Opdivo (nivolumab) and Yervoy (ipilimumab), which are immunotherapy drugs created by Bristol-Myers Squibb. It is the first new drug combination approved for mesothelioma in 16 years. The most recent[…]

Read More »

New Immuno-Radiology Treatment Being Tested on Mesothelioma

Mesothelioma is a cancer with a bad prognosis that is primarily caused by asbestos exposure. There is no cure for mesothelioma, so people diagnosed with the disease do not have a great chance of living long past their diagnoses. Clinical trials are people’s best chance of finding a better treatment[…]

Read More »

Mesothelioma Trial Involving UV1 Cancer Vaccine and Immunotherapy

A new mesothelioma clinical trial is taking place in Oslo, Norway. The trial is looking at the UV1 cancer vaccine alongside immunotherapy. The vaccine is a peptide-based drug that activates a T-cell response, allowing the immunotherapy drugs to work better. This will be the first time that UV1 is being[…]

Read More »

Quinacrine has Anti-Cancer Effects on Mesothelioma Cells

Pleural mesothelioma is a devastating cancer of the mesothelium, which is a lining of different organs. The most common type of mesothelioma is pleural, which affects the lining of the lungs while the second most common is peritoneal, which surrounds the lining of the abdomen. New treatments are constantly being[…]

Read More »

Keytruda and Tumor Treating Fields Combination Could Soon be Used for Mesothelioma

A clinical trial being tested on lung cancer could potentially be a good treatment for people with mesothelioma. The combination of Keytruda and Tumor Treating Fields is being tested for non-small cell lung cancer. Keytruda is an immune checkpoint inhibitor that allows the immune system to find cancer cells hiding[…]

Read More »

Opdivo and Yervoy Combination Could Lengthen Aggressive Mesothelioma Sufferers’ Lives

The combination of Yervoy and Opdivo was tested on mesothelioma and the overall survival was promising.   The overall survival was 18.1 months versus 14.1 months for patients receiving just chemotherapy. This is the first time that a phase III trial had an improved survival with an immunotherapy combination in a[…]

Read More »

Genetically Modified T-Cells for the Treatment of Mesothelioma and Other Tumors

Genetically modified T cells are a promising treatment for those suffering from mesothelioma. There is only data from five patients, but the results so far look good. The Phase I part of the study is looking at the safety and efficacy of the treatment and is finding out what dosage[…]

Read More »

More Peritoneal Mesothelioma Patients Should be Receiving Surgery

Peritoneal mesothelioma is a rare condition with only 400 cases diagnosed every year. Patients diagnosed with the cancer are not living as long as they could because of the underutilization of surgery. Surgery is only performed on a third of patients even though there are people that would benefit and[…]

Read More »

A New Study is Looking at the Combination of Keytruda and ONCOS-102

A new combination of two existing drugs is being tested to treat mesothelioma. Merck and Targovax, which have the drugs Keytruda (pembrolizumab), an immunotherapy drug, and ONCOS-102, a modified adenovirus, are working together in the study. They can both be used on their own alongside chemotherapy to treat mesothelioma, but[…]

Read More »